How Fast Does HSIL Turn Into Cancer?

HSIL, or high-grade squamous intraepithelial lesion, does not flip into cancer on a predictable schedule. When progression does happen, it typically unfolds over years to decades, not weeks or months. And a large share of HSIL lesions never become cancer at all. In large studies of cervical HSIL (specifically the CIN2 subtype), roughly 60 percent of cases regress on their own without treatment. The timeline and likelihood of progression depend heavily on which HPV strain is involved, where in the body the lesion sits, and how the immune system responds.

How Often Cervical HSIL Regresses on Its Own

One of the most consistent findings across studies is that a majority of cervical HSIL classified as CIN2 will spontaneously clear. In a large study of over 11,000 women under active surveillance, about 63 percent of CIN2 lesions regressed within 24 months, while roughly a third progressed to CIN3 during the same window. Most of the action happened early: 90 percent of women who were going to regress or progress did so within the first 12 months.¹ A smaller prospective study found a nearly identical pattern, with 60 percent of confirmed CIN2 cases regressing over a median follow-up of 20 months.²

These numbers come with important context. CIN2 is the lower end of the HSIL spectrum. CIN3 lesions, which represent more advanced precancerous change, are less likely to resolve without treatment and carry a higher risk of eventually becoming invasive cancer. Historically, the strongest evidence for CIN3 progression comes from a controversial study in New Zealand where, between 1965 and 1974, treatment was deliberately withheld from women with CIN3. That study showed a substantial long-term risk of invasive cancer when high-grade lesions were left completely untreated over decades.³ No ethical modern study would replicate that design, so most current data on natural regression focuses on CIN2, where watchful waiting is considered acceptable in many clinical scenarios.

What Speeds Up or Slows Down Progression

The single biggest factor is which HPV strain is causing the infection. HPV-16 is the most common high-risk type and also one of the most persistent. Women infected with HPV-16 are significantly less likely to see their CIN2 lesions regress spontaneously. In one study, only about 42 percent of HPV-16-positive CIN2 cases regressed, compared with 71 percent of cases caused by other HPV types.² Another study found that infection by HPV other than HPV-16 was the strongest predictor of spontaneous regression, with more than five times the odds of clearing compared to HPV-16 cases.⁴

HPV-18 may play a different and somewhat alarming role. Classic research found that HPV-18 was strikingly underrepresented in precancerous lesions (only about 3 percent of intraepithelial neoplasia) but accounted for roughly 22 percent of invasive cervical carcinomas. The proposed explanation is that HPV-18 spends less time in the precancerous stage and moves more quickly to invasion, essentially sprinting through the window where screening would catch it.⁵

At the molecular level, progression depends on what two viral proteins called E6 and E7 are doing inside the cell. E6 disables p53, a protein the body relies on to catch damaged cells and trigger their destruction. E7 interferes with the retinoblastoma protein, which normally acts as a brake on cell division. When both are knocked out, cells keep dividing even when they shouldn’t, and damaged DNA accumulates unchecked.⁶ The key transition happens when HPV’s genetic material shifts from floating freely inside the cell to integrating into the cell’s own chromosomes. Once integrated, the virus produces E6 and E7 more persistently, and the risk of progression climbs.⁷

Does Age Matter?

You might assume younger women have a better chance of clearing HSIL because their immune systems are more robust. The reality is less straightforward. One study found that when CIN2 cases in women aged 25 to 40 were surgically excised, about 25 percent turned out to already contain CIN3 or worse, compared to 7 percent in women under 25. That sounds like age is a risk factor, but after adjusting for HPV type and cytology results, age itself was no longer a significant predictor.⁸ Multiple studies have reached a similar conclusion: the regression rate of CIN2 supports conservative management regardless of age, and age alone should not dictate whether a woman gets immediate surgery or is monitored over time.⁹

What does matter more than age is what the initial Pap smear and colposcopy look like. Women whose index cytology showed high-grade changes had a significantly higher risk of progressing compared to those whose cytology appeared normal, with an adjusted relative risk of about 1.6.¹ In other words, the severity of the lesion as seen under the microscope and on colposcopy tells you more about what’s likely to happen than the patient’s birthday does.

Active Surveillance and Why CIN2 Diagnosis Is Tricky

Given the high spontaneous regression rate, many guidelines now allow a period of active surveillance for CIN2, particularly in younger women who may want to preserve fertility. A 48-month follow-up study of 237 HPV-positive women with CIN2 found that about 61 percent regressed, 13 percent persisted, and roughly a quarter progressed to CIN3. No invasive carcinoma developed during the entire follow-up period.¹⁰

There is a wrinkle that makes this trickier than it sounds. CIN2 is notoriously hard for pathologists to agree on. The diagnosis sits in an ambiguous zone between clearly low-grade and clearly high-grade changes, and different pathologists looking at the same tissue sample frequently disagree. Some researchers have argued that the apparent “progression” seen in surveillance studies may partly reflect cases where the initial biopsy was misread as CIN2 when the lesion was actually CIN3 all along.¹¹ This diagnostic fuzziness means that whenever you see a statistic like “a third of CIN2 progresses,” some of that progression was probably baked in from the start by an initially uncertain diagnosis.

What Happens After Treatment

When HSIL is treated rather than watched, the standard options for cervical lesions include loop electrosurgical excision (LEEP), cryotherapy, and cold knife conization. All of them are effective. LEEP and cryotherapy carry a recurrence rate of about 5 percent, while cold knife conization brings recurrence down to roughly 1 percent.¹² Even in cases where the surgical margins come back positive, meaning abnormal cells extended to the edge of the removed tissue, the vast majority of women remain disease-free. One study found that among patients with HSIL and positive margins after LEEP, about 89 percent had no recurrence.¹³

The broader point is that treated cervical HSIL very rarely turns into cancer. The entire screening and treatment system is designed to intercept the process at this precancerous stage, and it works well. The overwhelming majority of cervical cancers diagnosed today occur in women who were never screened or who fell out of follow-up after an abnormal result.

HSIL in the Cervix During Pregnancy

Pregnancy creates an unusual immunological and hormonal environment that can affect how HSIL behaves. Research suggests that the postpartum period is associated with significant regression of cervical HSIL, possibly because hormonal shifts and immune reactivation after delivery help clear the underlying HPV infection. Studies have found higher levels of stromal inflammation in the cervical tissue of pregnant women with HSIL, which may reflect immune activity that ultimately aids in clearing the virus.¹⁴ For this reason, cervical HSIL discovered during pregnancy is almost always monitored rather than treated, with the expectation that intervention can be reassessed after delivery.

Anal HSIL Follows a Different Pace

HSIL doesn’t only develop in the cervix. The same HPV-driven process can produce high-grade lesions in the anus, and the progression dynamics there are distinct enough to deserve separate attention. In the general population, the rate of progression from anal HSIL to invasive anal cancer is estimated at about 5 percent.¹⁵ That rate is considerably higher in people at elevated risk, particularly HIV-positive men who have sex with men. In that group, anal HSIL that was already present at the start of follow-up progressed to cancer over an average of about 57 months, while newly detected HSIL took roughly 64 months.¹⁶

A landmark trial published in the New England Journal of Medicine demonstrated that treating anal HSIL cut the progression rate to anal cancer by 57 percent compared to active monitoring alone. The treatment group developed cancer at a rate of 173 per 100,000 person-years, while the monitoring group saw 402 per 100,000 person-years.¹⁷ That trial provided the first randomized evidence that treating anal HSIL, rather than just watching it, meaningfully reduces cancer incidence in high-risk individuals.

Vulvar HSIL and the Two-Track Problem

HSIL of the vulva presents yet another timeline, and one that splits into two dramatically different paths depending on the underlying cause. Most vulvar HSIL is HPV-driven and behaves relatively slowly. In a large Dutch cohort, HPV-associated vulvar HSIL carried a 10-year cancer risk of about 8 percent.¹⁸ The cumulative risk climbed more steeply in the first five years and then leveled off somewhat, reaching roughly 16 percent after more than 25 years of follow-up.¹⁹

The other pathway is far more dangerous. Differentiated vulvar intraepithelial neoplasia, or dVIN, is not caused by HPV. It arises instead from chronic inflammatory skin conditions such as lichen sclerosus and involves mutations in the p53 gene. This type of precancer progresses much faster and more often. In the same Dutch cohort, roughly 46 percent of dVIN patients developed vulvar cancer within just five years.²⁰ The 10-year cancer risk for HPV-independent dVIN with p53 mutations reached about 67 percent, dwarfing the 8 percent seen in HPV-associated HSIL.¹⁸ The clinical upshot is that vulvar HSIL caused by HPV is manageable with monitoring and treatment, while dVIN demands urgent and aggressive intervention.

Researchers are actively looking for better ways to identify which vulvar HSIL patients face the highest risk. One promising approach is DNA methylation testing. In a population-based study, positive methylation status was the only prognostic factor that predicted vulvar cancer development in HPV-associated HSIL. Women with methylation-positive HSIL who did not receive radical excision had a five-year cancer risk of about 8 percent, compared with just 1.4 percent in methylation-negative cases.²⁰ If validated more broadly, this kind of test could eventually help clinicians decide who needs surgery and who can safely be monitored.

How HPV Vaccination Changes the Equation

The most effective way to prevent HSIL from forming in the first place is HPV vaccination. Over the past decade, evidence has consistently shown that HPV vaccines reduce both cervical infections and precancerous lesions at the individual level, and that population-wide vaccination programs measurably reduce the overall burden of cervical disease.²¹ Current vaccines target the HPV types responsible for the vast majority of HPV-driven cancers, including HPV-16 and HPV-18, the two strains most strongly linked to rapid or aggressive progression.

Vaccination does not help people who already have an established HPV infection or existing HSIL. But for populations that were vaccinated before exposure, the rates of high-grade cervical lesions have dropped sharply, and the downstream effect on cervical cancer incidence is beginning to show up in cancer registries in countries with high vaccination coverage. The timeline question in the article’s title is, in a sense, becoming less relevant for younger vaccinated cohorts, because fewer of them will ever develop HSIL at all. For unvaccinated individuals and those already living with HSIL, the progression dynamics described above still apply in full.

1
American Journal of Obstetrics and Gynecology. Regression and progression of cervical intraepithelial neoplasia grade 2
2
PubMed. Factors predicting the spontaneous regression of cervical high-grade squamous intraepithelial lesions (HSIL/CIN2)
3
PubMed. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study
4
PubMed. Regression of cervical high-grade squamous intraepithelial lesions (HSIL/CIN2) managed expectantly
5
American Journal of Obstetrics and Gynecology. Analysis of individual cervical human papillomavirus types in neolasia: A possible role for type 18 in rapid progression
6
Critical Reviews in Oncology/Hematology. Novel therapeutic strategies for targeting E6 and E7 oncoproteins in cervical cancer
7
PubMed Central. Risk of progression of early cervical lesions is associated with integration and persistence of HPV-16 and expression of E6, Ki-67, and telomerase
8
PubMed Central. Risk stratification and conservative management of women aged 25–40 years with cervical intraepithelial neoplasia grade 2(CIN2)
9
PubMed. Predictor factors for conservative management of cervical intraepithelial neoplasia grade 2: Cytology and HPV genotyping
10
PubMed Central. CIN2 and Active Surveillance: Evidence from 48-Month Follow-Up in an HPV-Positive Cohort
11
American Journal of Obstetrics & Gynecology. Prognostic significance of expert-verified histological diagnoses in women undergoing active surveillance for cervical intraepithelial neoplasia grade 2
12
International Journal of Gynecology & Obstetrics. Systematic reviews and meta-analyses of benefits and harms of cryotherapy, LEEP, and cold knife conization to treat cervical intraepithelial neoplasia
13
PubMed Central. Factors that influence persistence or recurrence of high-grade squamous intraepithelial lesion with positive margins after the loop electrosurgical excision procedure: a retrospective study
14
Annals of Clinical & Laboratory Science. Comparison of Cervical HSIL Outcome between Pregnant and Non-Pregnant Women
15
PubMed Central. Screening, Surveillance, and Treatment of Anal Intraepithelial Neoplasia
16
PubMed. Progression of anal high-grade squamous intraepithelial lesions to invasive anal cancer among HIV-infected men who have sex with men
17
PubMed Central. Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer
18
PubMed. High-grade vulvar intraepithelial neoplasia: comprehensive characterization and long-term vulvar carcinoma risk
19
PubMed Central. Vulvar intraepithelial neoplasia: Incidence and long‐term risk of vulvar squamous cell carcinoma
20
PubMed. DNA methylation testing for vulvar cancer risk stratification in patients with high-grade vulvar intraepithelial neoplasia: a population-based cohort study
21
PubMed Central. Monitoring HPV vaccine impact on cervical disease: Status and future directions for the era of cervical cancer elimination